Clinical Trial

Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

Study acronym: BALCoS/DiLCoS
Completed
View on ClinicalTrials.gov →
Summary
The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients in the cohort can also join the Digital Long COVID Study (DiLCoS), a single-arm, cohort-based proof-of-feasibility study that is part of the larger BALCoS. DiLCoS is a intervention substudy designed to evaluate whether doing exercises delivered via a smartphone app (referred as digital intervention) can help with PCC. The digital intervention is a 12-week program that includes different kinds of exercises like breathing exercises, relaxation techniques, and tips on managing fatigue and other symptoms. It also teaches patients how to monitor their activities and energy levels, and provides psychological exercises to cope with negative thoughts and pain. Patients in the cohort complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-30
notable Enrollment increased: 120 -> 196 participants 2026-07-30
notable Primary completion pushed: 2026-04 -> 2026-05-06 2026-07-30
minor Completion pushed: 2026-04 -> 2026-05-06 2026-07-30
Trial Details
NCT Number NCT05781893
Lead Sponsor University Hospital, Basel, Switzerland
Collaborators: State Secretariat for Education Research and Innovation, Switzerland, Horizon Europe
Conditions Post COVID-19 Condition (PCC)
Enrollment 196 participants
Start Date 2023-04-20
Primary Completion 2026-05-06 (estimated)
Study Completion 2026-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-29